XML 33 R10.htm IDEA: XBRL DOCUMENT
v3.25.2

Fair Value Measurements | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2025 | Dec. 31, 2024
Fair Value Disclosures [Abstract] |  |
Fair Value Measurements | 4. Fair Value Measurements The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):
|  | March 31, 2025 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oramed Note |  | $ | 14,962 |  |  | $ | — |  |  | $ | — |  |  | $ | 14,962 |
Tranche B Notes |  |  | 24,480 |  |  |  | — |  |  |  | — |  |  |  | 24,480 |
Purchased revenue liability |  |  | 7,300 |  |  |  | — |  |  |  | — |  |  |  | 7,300 |
Derivative liabilities |  |  | 7,894 |  |  |  | — |  |  |  | — |  |  |  | 7,894 |
Other long-term liabilities |  |  | 155 |  |  |  | — |  |  |  | — |  |  |  | 155 |
Total liabilities measured at fair value |  | $ | 54,791 |  |  | $ | — |  |  | $ | — |  |  | $ | 54,791 |
|  | December 31, 2024 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oramed Note |  | $ | 12,161 |  |  | $ | — |  |  | $ | — |  |  | $ | 12,161 |
Tranche B Notes |  |  | 23,560 |  |  |  | — |  |  |  | — |  |  |  | 23,560 |
Purchased revenue liability |  |  | 6,800 |  |  |  |  |  |  |  |  |  |  |  | 6,800 |
Derivative liabilities |  |  | 18,303 |  |  |  | — |  |  |  | — |  |  |  | 18,303 |
Other long-term liabilities |  |  | 155 |  |  |  | — |  |  |  | — |  |  |  | 155 |
Total liabilities measured at fair value |  | $ | 60,979 |  |  | $ | — |  |  | $ | — |  |  | $ | 60,979 |
The Oramed Note In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $101.9 million (the “Oramed Note”) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level 3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of March 31, 2025 and December 31, 2024 was determined to be $15.0 million and $12.2 million, respectively, by applying a discount rate of 129.07% and 128.82%, respectively. For the three months ended March 31, 2025 and 2024, the Company recorded a loss of $2.8 million and $3.8 million in change in fair value of the Oramed Note in the unaudited condensed consolidated statements of operations, respectively. Tranche B Notes In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $50.0 million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Tranche B Notes are measured at fair value on a recurring basis using Level 3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of March 31, 2025 and December 31, 2024, was determined to be $24.5 million and $23.6 million, respectively. For the three months ended March 31, 2025, the Company recorded a loss of $2.5 million in change in fair value of the Tranche B Notes in the unaudited condensed consolidated statement of operations. Purchased Revenue Liability In October 2024, the Company entered into a Purchase and Sale Agreement (“ZTlido Royalty Purchase Agreement”) with certain institutional investors (collectively, the “ZTlido Royalty Investors”) and Oramed (see Note 7). In February 2025, the Company also entered into a Purchase and Sale Agreement (“Gloperba-Elyxyb Royalty Purchase Agreement”) with certain institutional investors (collectively, the “Gloperba-Elyxyb Royalty Investors”) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability for both agreements with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The aggregate fair value of both agreements as of March 31, 2025 and December 31, 2024, was determined to be $7.3 million and $6.8 million, respectively. For the three months ended March 31, 2025, the Company recorded a loss of $0.8 million in change in fair value of the purchased revenue liability in the unaudited condensed consolidated statement of operations. Derivative Liabilities The Company recorded a gain of $10.4 million for the three months ended March 31, 2025, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, Deposit Warrant, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each as defined below). The Company recorded a loss of $0.5 million for the three months ended March 31, 2024, attributed to warrant liability consisting of the Private Warrants and the February 2024 BDO Firm Warrants. The Company assumed the private placement warrants from Vickers in November 2022 in connection with the Business Combination (the “Private Warrants”). As of March 31, 2025, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: 1,000,000 Private Warrants, which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock, 3,803,447 February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock, 15,000,000 April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock, 3,250,000 Deposit Warrant, which are currently exercisable for an aggregate of up to 3,250,000 shares of Common Stock, 7,500,000 October 2024 Noteholder Warrants, which are currently exercisable for an aggregate of up to 214,284 shares of Common Stock, and 57,512,958 December 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock. As of March 31, 2025, the fair value of derivative warrant liabilities related to these warrants was $7.9 million. The following table includes a summary of the derivative liabilities measured at fair value during the three months ended March 31, 2025 (in thousands):
|  | Fair Value |
Ending Balance as of December 31, 2024 |  | $ | 18,303 |
Change in fair value measurement |  |  | (10,409 | )
Ending Balance as of March 31, 2025 |  | $ | 7,894 |
Warrant Liability Measurement The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company’s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (as defined below), described in Note 9 of the Notes to Consolidated Financial Statements in the Annual Report on Form 10-K. A summary of the inputs used in valuing the derivative warrant liabilities as of March 31, 2025 is as follows:
|  | Private Warrants |  |  | February 2024 BDO Firm Warrants |  |  | April 2024 RDO Common Warrants |  |  | Deposit Warrant |  |  | October 2024 Noteholder Warrants |  |  | December 2024 RDO Common Warrants (5yr) |  |  | December 2024 RDO Common Warrants (2.5yr) |
Exercise price |  | $ | 402.50 |  |  | $ | 59.50 |  |  | $ | 38.50 |  |  | $ | 1.20 |  |  | $ | 36.40 |  |  | $ | 22.72 |  |  | $ | 22.72 |
Term, in years |  |  | 2.61 |  |  |  | 3.93 |  |  |  | 4.07 |  |  |  | 4.22 |  |  |  | 4.52 |  |  |  | 4.70 |  |  |  | 2.20 |
Volatility |  |  | 109.0 | % |  |  | 85.0 | % |  |  | 83.0 | % |  |  | 76.0 | % |  |  | 80.0 | % |  |  | 79.0 | % |  |  | 98.0 | %
Risk-free rate |  |  | 3.85 | % |  |  | 3.88 | % |  |  | 3.89 | % |  |  | 3.89 | % |  |  | 3.90 | % |  |  | 3.91 | % |  |  | 3.85 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | %
A summary of the inputs used in valuing the derivative warrant liabilities as of December 31, 2024 is as follows:
|  | Private Warrants |  |  | February 2024 BDO Firm Warrants |  |  | April 2024 RDO Common Warrants |  |  | Deposit Warrant |  |  | October 2024 Noteholder Warrants |  |  | December 2024 RDO Common Warrants (5yr) |  |  | December 2024 RDO Common Warrants (2.5yr) |
Exercise price |  | $ | 402.50 |  |  | $ | 59.50 |  |  | $ | 38.50 |  |  | $ | 1.20 |  |  | $ | 36.40 |  |  | $ | 22.72 |  |  | $ | 22.72 |
Term, in years |  |  | 2.86 |  |  |  | 4.18 |  |  |  | 4.32 |  |  |  | 4.47 |  |  |  | 4.77 |  |  |  | 4.95 |  |  |  | 2.45 |
Volatility |  |  | 109.0 | % |  |  | 81.0 | % |  |  | 80.0 | % |  |  | 73.0 | % |  |  | 77.0 | % |  |  | 76.0 | % |  |  | 95.0 | %
Risk-free rate |  |  | 4.22 | % |  |  | 4.29 | % |  |  | 4.30 | % |  |  | 4.30 | % |  |  | 4.32 | % |  |  | 4.33 | % |  |  | 4.21 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | %
Contingent Consideration Related to SP-104 Acquisition The Development Milestone Payment related to the SP-104 Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $3.0 million in cash or shares of Common Stock to Aardvark, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of 9.6%. As of each of March 31, 2025 and December 31, 2024, the fair value of contingent consideration related to the Development Milestone Payment was $0.2 million. | 4. Fair Value Measurements The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):
|  | December 31, 2024 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oramed Note |  | $ | 12,161 |  |  | $ | — |  |  | $ | — |  |  | $ | 12,161 |
Tranche B Notes |  |  | 23,560 |  |  |  | — |  |  |  | — |  |  |  | 23,560 |
Purchased Revenue Liability |  |  | 6,800 |  |  |  | — |  |  |  | — |  |  |  | 6,800 |
Derivative liabilities |  |  | 18,303 |  |  |  | — |  |  |  | — |  |  |  | 18,303 |
Other long-term liabilities |  |  | 155 |  |  |  | — |  |  |  | — |  |  |  | 155 |
Total liabilities measured at fair value |  | $ | 60,979 |  |  | $ | — |  |  | $ | — |  |  | $ | 60,979 |
|  | December 31, 2023 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oramed Note |  | $ | 104,089 |  |  | $ | — |  |  | $ | — |  |  | $ | 104,089 |
Convertible Debentures |  |  | 4,340 |  |  |  | — |  |  |  | — |  |  |  | 4,340 |
Derivative liabilities |  |  | 1,518 |  |  |  | — |  |  |  | — |  |  |  | 1,518 |
Other long-term liabilities |  |  | 179 |  |  |  | — |  |  |  | — |  |  |  | 179 |
Total liabilities measured at fair value |  | $ | 110,126 |  |  | $ | — |  |  | $ | — |  |  | $ | 110,126 |
The Oramed Note In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $101.9 million (the “Oramed Note”) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of such note recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level 3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of December 31, 2024 and 2023 was determined to be $12.2 million and $104.1 million, respectively, by applying a discount rate of 128.82% and 13.05%, respectively. For the years ended December 31, 2024 and 2023, the Company recorded a loss of $3.6 million and $2.8 million in change in fair value of the Oramed Note, respectively. For the years ended December 31, 2024 and 2023, the change in fair value due to instrument-specific credit risk recorded as a component of other comprehensive income was $6.3 million and nil, respectively. During the year ended December 31, 2024 the Company reclassified $5.0 million from accumulated other comprehensive income to the consolidated statement of operations. This reclassification was related to the principal payments and partial conversion of the Oramed Note balance into the Tranche B Notes (see Note 7). FSF Deposit In June 2024, the Company received the FSF Deposit in the aggregate principal amount of $10.0 million from FSF Lender (see Note 2 and Note 7). The Company elected the fair value option to account for the FSF Deposit with any changes in the fair value of the deposit recorded in the consolidated statements of operations and comprehensive loss. For the year ended December 31, 2024, the Company recorded a loss of $4.7 million in change in fair value of the FSF Deposit in the consolidated statement of operations. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. Upon the satisfaction of the FSF Deposit, the Deposit Warrant became a freestanding instrument under ASC 480 and was included in derivative liabilities on the Company’s consolidated balance sheet. Tranche B Notes In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $50.0 million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Tranche B Notes are measured at fair value on a recurring basis using the Level 3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of December 31, 2024, was determined to be $23.6 million. For the year ended December 31, 2024, the Company recorded a gain of $6.6 million in change in fair value of the Tranche B Notes in the consolidated statement of operations. Purchased Revenue Liability In October 2024, the Company entered into the ZTlido Royalty Purchase Agreement with certain institutional investors (collectively, the “ZTlido Royalty Investors”) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The fair value as of December 31, 2024, was determined to be $6.8 million. For the year ended December 31, 2024, the Company recorded a loss of $0.9 million in change in fair value of the purchased revenue liability in the consolidated statement of operations. Convertible Debentures In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $25.0 million (see Note 7). The Convertible Debentures were measured at fair value on a recurring basis using Level 3 inputs. The Company used the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations and comprehensive loss. Interest expense related to the Convertible Debentures is included in the changes in fair value. For the years ended December 31, 2024 and 2023, the Company recorded a loss of $35.0 thousand and a loss of $4.4 million in change in fair value of the Convertible Debentures, respectively. The Company fully repaid the Convertible Debentures in March 2024. Derivative Liabilities The Company recorded a gain of $17.4 million for the year ended December 31, 2024, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each as defined below). The Company recorded a loss of $ 0.5 million for the year ended December 31, 2023, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination (“Private Warrants”) . As of December 31, 2024, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: 1,000,000 Private Warrants, which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock, 3,803,447 February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock, 15,000,000 April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock, 3,250,000 Deposit Warrant, which are currently exercisable for an aggregate of up to 3,250,000 shares of Common Stock, 7,500,000 October 2024 Noteholder Warrants , which are currently exercisable for an aggregate of up to 214,284 shares of Common Stock, and 57,512,958 December 2024 RDO Common Warrants , which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock . As of December 31, 2024, the fair value of derivative warrant liabilities related to these warrants was $18.3 million. The following table includes a summary of the derivative liabilities measured at fair value during the years ended December 31, 2024 and 2023 (in thousands):
|  | Fair Value |
Ending Balance as of December 31, 2022 |  | $ | 1,231 |
Change in fair value measurement |  |  | 512 |
Forfeiture of Private Warrants |  |  | (225 | )
Ending Balance as of December 31, 2023 |  |  | 1,518 |
Issuance of February 2024 BDO Firm Warrants as part of February 2024 BDO, April 2024 RDO Common Warrants as part of April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of December 2024 RDO, and December 2024 RDO Pre-Funded Warrants as part of December 2024 RDO |  |  | 34,330 |
Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit |  |  | 1,690 |
Cancellation of Private Warrants as part of Oramed Letter Agreement |  |  | (445 | )
Warrant amendment and exercise as part of December 2024 RDO |  |  | (428 | )
Settlement of December 2024 RDO Pre-Funded Warrants |  |  | (984 | )
Change in fair value measurement |  |  | (17,378 | )
Ending Balance as of December 31, 2024 |  | $ | 18,303 |
Warrant Liability Measurement The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company’s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9). A summary of the inputs used in valuing the derivative warrant liabilities is as follows:
|  | Private Warrants |  |  | February 2024 BDO Firm Warrants |  |  | April 2024 RDO Common Warrants |  |  | Deposit Warrant |  |  | October 2024 Noteholder Warrants |  |  | December 2024 RDO Common Warrants (5yr) |  |  | December 2024 RDO Common Warrants (2.5yr) |
|  | December 31, 2024 |
Exercise price |  | $ | 402.50 |  |  | $ | 59.50 |  |  | $ | 38.50 |  |  | $ | 1.20 |  |  | $ | 36.40 |  |  | $ | 22.72 |  |  | $ | 22.72 |
Term, in years |  |  | 2.86 |  |  |  | 4.18 |  |  |  | 4.32 |  |  |  | 4.47 |  |  |  | 4.77 |  |  |  | 4.95 |  |  |  | 2.45 |
Volatility |  |  | 109.0 | % |  |  | 81.0 | % |  |  | 80.0 | % |  |  | 73.0 | % |  |  | 77.0 | % |  |  | 76.0 | % |  |  | 95.0 | %
Risk-free rate |  |  | 4.22 | % |  |  | 4.29 | % |  |  | 4.30 | % |  |  | 4.30 | % |  |  | 4.32 | % |  |  | 4.33 | % |  |  | 4.21 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | %
|  | Private Warrants |
|  | December 31, 2023 |
Exercise price |  | $ | 402.50 |
Term, in years |  |  | 3.86 |
Volatility |  |  | 76.0 | %
Risk-free rate |  |  | 3.90 | %
Dividend yield |  |  | 0.0 | %
Contingent Consideration Related to SP-104 Acquisition The Development Milestone Payment related to the SP-104 Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $3.0 million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of 10.0%. As of December 31, 2024 and 2023, the fair value of contingent consideration related to the Development Milestone Payment was $0.2 million. There were no transfers between fair value measurement levels during the years ended December 31, 2024 and 2023.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration